LOPE vs COUR

For growth investors, Coursera, Inc.

(COUR) is the stronger pick with 9. 0% revenue growth year-over-year, versus 7. 1% for Grand Canyon Education, Inc. (LOPE). Grand Canyon Education, Inc. (LOPE) offers the better valuation at 21. 3x trailing P/E (16. 3x forward), making it the more compelling value choice. Analysts rate Grand Canyon Education, Inc. (LOPE) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Coursera, Inc.

is actually cheaper at 15. 2x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Grand Canyon Education, Inc.

(LOPE) delivered a total return of +74. 1%, compared to -82. 7% for Coursera, Inc. (COUR). Over 10 years, the gap is even starker: LOPE returned +272. 4% versus COUR's -86. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Grand Canyon Education, Inc.

(LOPE) is the lower-risk stock at 0. 35β versus Coursera, Inc. 's 0. 80β — meaning COUR is approximately 125% more volatile than LOPE relative to the S&P 500. On balance sheet safety, Coursera, Inc. (COUR) carries a lower debt/equity ratio of 1% versus 27% for Grand Canyon Education, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Coursera, Inc.

(COUR) is pulling ahead at 9. 0% versus 7. 1% for Grand Canyon Education, Inc. (LOPE). On earnings-per-share growth, the picture is similar: Coursera, Inc. grew EPS 39. 2% year-over-year, compared to -0. 3% for Grand Canyon Education, Inc.. Over a 3-year CAGR, COUR leads at 13. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Grand Canyon Education, Inc.

(LOPE) is the more profitable company, earning 19. 5% net margin versus -6. 7% for Coursera, Inc. — meaning it keeps 19. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LOPE leads at 27. 5% versus -10. 3% for COUR. At the gross margin level — before operating expenses — COUR leads at 54. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Coursera, Inc.

(COUR) trades at 15. 2x forward P/E versus 16. 3x for Grand Canyon Education, Inc. — 1. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for COUR: 24. 2% to $7. 79.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Grand Canyon Education, Inc.

(LOPE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 35), +272. 4% 10Y return). Both have compounded well over 10 years (LOPE: +272. 4%, COUR: -86. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Consumer Defensive sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.